Eikonoklastes Therapeutics
Eikonoklastes Therapeutics is an early stage biopharmaceutical company focused on rapidly developing innovative medicines for neurodegenerative diseases, starting with ALS. They aim to create breakthrough treatments with potential to significantly improve patient lives and lifespans, leveraging a pipeline focused on diseases with high unmet medical needs. Their approach includes first-in-class gene therapy platforms and accelerated clinical development strategies.
Industries
Nr. of Employees
small (1-50)
Eikonoklastes Therapeutics
Products
Neuron-targeted AAV-based gene therapy candidate for Caveolin-1 overexpression
A first-in-class AAV-based gene supplement therapy designed to overexpress Caveolin-1 in neurons to promote neuroprotection and improve neuromuscular signaling and function across neurodegenerative diseases; lead indication is amyotrophic lateral sclerosis with additional indications under preclinical evaluation.
Neuron-targeted AAV-based gene therapy candidate for Caveolin-1 overexpression
A first-in-class AAV-based gene supplement therapy designed to overexpress Caveolin-1 in neurons to promote neuroprotection and improve neuromuscular signaling and function across neurodegenerative diseases; lead indication is amyotrophic lateral sclerosis with additional indications under preclinical evaluation.
Services
Contract viral vector manufacturing partnerships
Collaboration with CDMOs to perform contract development and manufacturing for AAV-based viral vectors to support clinical translation.
CMC and process development for biologics and gene therapies
Development and optimization of manufacturing processes, analytical assays, and quality controls for gene therapy and antibody programs.
Contract viral vector manufacturing partnerships
Collaboration with CDMOs to perform contract development and manufacturing for AAV-based viral vectors to support clinical translation.
CMC and process development for biologics and gene therapies
Development and optimization of manufacturing processes, analytical assays, and quality controls for gene therapy and antibody programs.
Expertise Areas
- Gene therapy development for CNS indications
- Preclinical translational research in neurodegeneration
- CMC and process development for biologics and viral vectors
- AAV vector manufacturing and CDMO collaboration
Key Technologies
- AAV-mediated gene delivery (neuron-targeted capsids)
- Neuron-specific promoters for restricted transgene expression
- Intraspinal/subpial delivery techniques
- Gene overexpression (gene-supplement) therapeutics